Skip to main content
Premium Trial:

Request an Annual Quote

Correcting the Hype One Company at a Time

In this Forbes Q&A, Matthew Herper interviews James Thomson, who's recently started his own company, Cellular Dynamics International, which is focused on testing experimental drugs for heart side effects. Rather than cave into the hype surrounding regenerative medicine, he sees much bigger opportunities for stem cells as a research tool and in drug discovery. "It's hard to predict the future, but my guess is 20 years from now if you look backwards, 90 percent of the value of these cells will be in things that don't make the front pages. It will be things like drug screening, which is kind of boring, but it does get drugs to market that are safer and faster," he says.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.